|
|
Post by longstocking on Dec 23, 2015 18:08:07 GMT -5
For all of you bitching, this guy is a good pick. Smart, scrappy and knows how to play street ball. Built Insulet from nothing (i.e. began as CEO when com was pre-commercialization) to a player in the insulin pump market when it was dominated by MDT and J&J. Insulet is now #2 in the pump market. He's also a guy who gets shit done. Excellent, excellent choice. The one thing Mannkind did not need is a big company CEO who has never or had not recently run a smaller company as these guys can piss away money like its water. Very good move. Do you think Google and Dexcom could have had input on this decision? |
|
|
|
Post by james on Dec 23, 2015 18:08:11 GMT -5
13 (14?) years running a 2B medical device company making diabetic products. That seems like a great fit, as good as I dared hope for. I can't find anything on his age so far, but he doesn't appear especially old to me and it seems like to come out of retirement, he must be excited about the opportunity. A big element here is that this should demonstrate some confidence.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 23, 2015 18:10:33 GMT -5
13 (14?) years running a 2B medical device company making diabetic products. That seems like a great fit, as good as I dared hope for. I can't find anything on his age so far, but he doesn't appear especially old to me and it seems like to come out of retirement, he must be excited about the opportunity. A big element here is that this should demonstrate some confidence. His age is not an issue. Wait until you hear him on the first call. Hakan was a wet noodle. This guy is pure east coast, no BS and won't mince words. |
|
|
|
Post by cfield23 on Dec 23, 2015 18:14:09 GMT -5
13 (14?) years running a 2B medical device company making diabetic products. That seems like a great fit, as good as I dared hope for. I can't find anything on his age so far, but he doesn't appear especially old to me and it seems like to come out of retirement, he must be excited about the opportunity. A big element here is that this should demonstrate some confidence. His age is not an issue. Wait until you hear him on the first call. Hakan was a wet noodle. This guy is pure east coast, no BS and won't mince words. Scott, did you listen to him w/ $PODD?? Have you followed Insulet? It seems like this guy's a good choice, but would love to learn more about him. |
|
|
|
Post by kbrion77 on Dec 23, 2015 18:15:46 GMT -5
From Insulet's Q2-14 conference call:
"For the second quarter, we reported consolidated revenue of $72 million representing 20% growth over the same period last year. Demand for the new OmniPod remains high as evidenced by 35% OmniPod revenue growth year-over-year as our easily used water proof tubeless design continues to appeal to customers especially in key demographics such as children. Over 35% of our new patient starts this year are children under the age of 18 with nearly 40% of them aged 10 and under
."
Better believe he is going to go after this demographic as well and urge Sanofi to fast track that pediatric trial. Again very excited for this hire, for those of you that wanted a young CEO that knows how to tweet, sorry.
|
|
|
|
Post by alethea on Dec 23, 2015 18:22:09 GMT -5
13 (14?) years running a 2B medical device company making diabetic products. That seems like a great fit, as good as I dared hope for. I can't find anything on his age so far, but he doesn't appear especially old to me and it seems like to come out of retirement, he must be excited about the opportunity. A big element here is that this should demonstrate some confidence. He is 63 years old. |
|
|
|
Post by hawaiiguy42 on Dec 23, 2015 18:23:22 GMT -5
I was hoping for someone younger and more dynamic that knew how to use social media to communicate with shareholders. Not somebody coming out of retirement. Well I for one looked at the stock chart during his tenure... prior to his retirement, not shabby at all. Just remember, older means or equals to experience, knowledge and know-how. Do you really want some youngster learning the ropes... especially at this stage of the game. Not me. |
|
|
|
Post by afrizzle on Dec 23, 2015 18:23:59 GMT -5
I'm happy he's aware MannKind has shareholders
|
|
|
|
Post by dhandho on Dec 23, 2015 18:24:25 GMT -5
I am particularly fond of investing scenarios, where expectations are so low that any good news have asymmetrical appreciation on the share price. I am excited about the new CEO Duane Desisto. Doing some quick research tells me this guy is a veteran of the diabetes sector, been instrumental in developing a device for insulin delivery. During his 13 years at Insulet, the share price had moved from $3 to $50, this should bring some solace to the unsatisfied MNKD shareholders, we are all sailing in a similar boat.
MNKD is in a very difficult situation pertaining to its finances, slow Afrezza uptake, insurance tiers, new management and Technosphere yet to realise any new partner or application. Now, one could assess this situation as a half glass empty, but I personally being a overly optimistic person sees this as a half glass full situation. We have checked one box now with the new CEO taking over Al Mann. Hopefully, we will start to hear steady stream of good news in 2016. It seems Sanofi will continue the partnership through 2016 and will unleash Afrezza's potential.
I feel Afrezza is an awesome product and needs an effective leadership, hopefully, Mr. Desisto will get this insulin to millions of diabetics around the world.
|
|
|
|
Post by mssciguy on Dec 23, 2015 18:27:29 GMT -5
Sanofi---- "With or without you" -- Happy New Year!
|
|
|
|
Post by longstocking on Dec 23, 2015 18:29:50 GMT -5
For all of you bitching, this guy is a good pick. Smart, scrappy and knows how to play street ball. Built Insulet from nothing (i.e. began as CEO when com was pre-commercialization) to a player in the insulin pump market when it was dominated by MDT and J&J. Insulet is now #2 in the pump market. He's also a guy who gets shit done. Excellent, excellent choice. The one thing Mannkind did not need is a big company CEO who has never or had not recently run a smaller company as these guys can piss away money like its water. Very good move. Do you think Google and Dexcom could have had input on this decision? Admittedly, I like trying to connect dots, but I think I just answered my own question. www.businesswire.com/news/home/20140613005895/en/DexCom%E2%80%99s-Forthcoming-Mobile-App-Platform-Integrate-DataIt seems that Terry Gregg of Dexcom, (formerly President of Minimed), has a history with Duane that might prove useful in a DXCM/GOOG/SNY/MNKD relationship. |
|
|
|
Post by jpg on Dec 23, 2015 18:31:00 GMT -5
He comes from a very innovative and 'cutting edge' company which is certainly a plus. You mean Omni Pod? Yes absolutely. They muscled in on some rather big competitors and did very very well. Don't know if this is a prelude to Sanofi going it's separate way but this is the type of guy I would like to have 'driving' if we were free of a certain 'directionally challenged' BP. And honestly at this point I really do think that Mannkind could have done much better on it's own so far (save for the $ obviously...). Maybe not with our past CEO and staff but maybe with a guy (and his team) who understands the 'commercial diabetic trenches'. Now we need money (and to be dumped by Sanofi). I don't know much about him yet but the little I do know makes me feel much better about Mannkind. And I don't get many of the negative comments? Some of the above stuff leaves me truly perplex as to what some were looking for in a CEO? |
|
|
|
Post by hawaiiguy42 on Dec 23, 2015 18:33:34 GMT -5
Now that is very interesting.  |
|
|
|
Post by cjc04 on Dec 23, 2015 18:33:51 GMT -5
Is he the right choice?
Can he develop the pipeline?
Can he help bring Afrezza to its full potential?
I was happier thinking that none of these things mattered and a deal was already done with SNY.
|
|
|
|
Post by spiro on Dec 23, 2015 18:34:00 GMT -5
Interesting, Maybe he will start acquiring MNKD shares with some of his loose change. Duane DeSisto Executive Compensation As Former President and Chief Executive Officer at INSULET CORP, Duane DeSisto made $8,214,058 in total compensation. Of this total $370,000 was received as a salary, $0 was received as a bonus, $1,006,557 was received in stock options, $5,415,840 was awarded as stock and $1,421,661 came from other types of compensation. This information is according to proxy statements filed for the 2014 fiscal year. Former President and Chief Executive Officer INSULET CORP View local and national averages for salaries $8.2 MILLION $370,000 Base Pay $0 Bonus + Non-EquityIncentive Comp $370,000 Total Cash Comp $5,415,840 Stock Award Value $1,006,557 Option Award Value $6,422,397 Total Equity $1,421,661 Total Other $8,214,058 Total Compensatio www1.salary.com/Duane-DeSisto-Salary-Bonus-Stock-Options-for-INSULET-CORP.html |
|
